title: A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.
abstract: BACKGROUND
  A prospective randomized study was carried out in two centres to compare the number of oocytes retrieved after two different starting doses of recombinant human FSH (rhFSH) (Gonal-F) in women undergoing ovarian stimulation for IVF/intracytoplasmic sperm injection (ICSI) cycles using the multiple dose regimen of the gonadotrophin-releasing hormone (GnRH) antagonist cetrorelix (Cetrotide) to prevent induction of the premature LH surge.
  
  
  METHODS
  Sixty women were randomized to receive rhFSH 150 IU ('low'), and 60 women to receive rhFSH 225 IU ('high') as the starting dose for the first 5 days of stimulation. From stimulation day 6 and onwards, including the day of human chorionic gonadotrophin (HCG) administration, the women received 0.25 mg of cetrorelix as a daily dose. The primary endpoint was the number of oocytes retrieved.
  
  
  RESULTS
  The mean number (+/- SD) of oocytes was 9.1 +/- 4.4 and 11.0 +/- 4.6 in the 'low' and 'high' groups respectively (P = 0.024). The mean number of 75 IU ampoules of rhFSH was significantly lower in the 'low' group (23.0 +/- 6.3 versus 30.5 +/- 5.6, P < 0.0001). The ongoing pregnancy rate per started cycle and per embryo transfer were 25.9 and 28.8% versus 25.4 and 26.8% respectively in the 'low' and 'high' rhFSH groups (P = NS).
  
  
  CONCLUSIONS
  When using a starting dose of 225 IU rhFSH combined with the multiple dose of 0.25 mg cetrorelix from stimulation day 6, significantly more oocytes were obtained than with a starting dose of 150 IU rhFSH.
authors.affiliation: Fertilitetscentrum, Carlander's Hospital, Göteborg, Sweden. matts.wikland@fcivf.com
authors.forename: M
authors.initials: M
authors.lastname: Wikland
authors.forename: C
authors.initials: C
authors.lastname: Bergh
authors.forename: K
authors.initials: K
authors.lastname: Borg
authors.forename: T
authors.initials: T
authors.lastname: Hillensjö
authors.forename: C M
authors.initials: CM
authors.lastname: Howles
authors.forename: A
authors.initials: A
authors.lastname: Knutsson
authors.forename: L
authors.initials: L
authors.lastname: Nilsson
authors.forename: M
authors.initials: M
authors.lastname: Wood
mesh_terms: D002452:Cell Count; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D015925:Cryopreservation; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D009865:Oocytes; D010062:Ovulation Induction; D011247:Pregnancy; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage; D020554:Sperm Injections, Intracytoplasmic; D020858:Tissue and Organ Harvesting; D016896:Treatment Outcome
chemical_list: D006063:Chorionic Gonadotropin; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone; C062876:cetrorelix